Results 11 to 20 of about 589,499 (392)
Experience with Dopamine Agonists in the Treatment of Prolactinomas [PDF]
Acta Medica Lituanica, 2022 The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of ...
Nadiya Barabash, Tetiana M. Tykhonova
doaj +2 more sources
Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease [PDF]
Frontiers in NeurologyIntroductionImpulse control disorders (ICDs) are defined as excessive and repetitive behaviors that may affect Parkinson’s disease (PD) patients exposed to dopamine agonists. Current data on ICDs in patients with early-onset Parkinson’s disease (EOPD) is
Pierpaolo Turcano +8 more
doaj +2 more sources
Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists [PDF]
Clinical Parkinsonism & Related Disorders, 2021 Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral.
Mohammad Edrees Mohammad +6 more
doaj +2 more sources
Impulse control disorders and dopamine agonists [PDF]
European Psychiatry, 2021 Introduction Impulse control disorders (ICDs) are an adverse effect of dopamine agonists (DAAs) that affects the quality of life and can lead to legal, criminal and familiar problems.
D. Martins +3 more
doaj +2 more sources
Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa? [PDF]
Frontiers in Nutrition, 2014 Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight and an often delusional quality of
Guido eFrank
doaj +4 more sources
Nature Communications, 2018 Dopamine receptor agonists are used for the treatment of various psychiatric diseases. Here, the authors screen approximately three million compounds and identify a novel class of D1R agonists that do not have a catechol scaffold and possess promising ...
David L. Gray +12 more
doaj +2 more sources
Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report [PDF]
European Psychiatry, 2022 Introduction We present the case of a 65-year-old woman with multiple and chronic psychosomatic symptoms. Due to motor impairments she was diagnosed in 2009 with Parkinson’s Disease (PD) by the neurology department and empirical treatment with levodopa ...
M.L. Costa, A. Cerame
doaj +2 more sources
Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
Frontiers in Pharmacology, 2020 Dopamine receptors are widely distributed within the brain where they play critical modulator roles on motor functions, motivation and drive, as well as cognition.
Jean Claude Martel +1 more
doaj +2 more sources
Pharmaceuticals, 2023 We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric +24 more
doaj +1 more source
Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]
PLoS ONE, 2014 BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko +4 more
doaj +1 more source